Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antisense Oligonucleotide
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : n-Lorem Foundation
Deal Size : Undisclosed
Deal Type : Partnership
Details : Partnership will support the n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Antisense Oligonucleotide
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : n-Lorem Foundation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Pharmaxis
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial
Details : The phase 1c/2a trial MF‐101 aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2021
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Pharmaxis
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cobitolimod
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : InDex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CONCLUDE is a randomised, double-blind, placebo-controlled, global phase III study to evaluate cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.
Brand Name : Kappaproct
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 30, 2021
Lead Product(s) : Cobitolimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : InDex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Foralumab
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Tiziana Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.
Brand Name : TZLS-401
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 11, 2020
Lead Product(s) : Foralumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Tiziana Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?